Showing 3031-3040 of 4063 results for "".
- New Guidance Issued on Paycheck Protection Program Loanshttps://modernod.com/news/new-guidance-issued-on-ppp-loans/2477525/New guidance was posted to the Treasury website regarding the Paycheck Protection Program (PPP), which authorizes up to $349 billion toward job retention and certain other expenses for s
- President of Glaucoma Research Foundation Issues Messagehttps://modernod.com/news/president-of-glaucoma-research-foundation-issues-message/2477429/The Glaucoma Research Foundation sent an email to its membership on Friday, answering questions that glaucoma specialists may have during the COVID-19 pandemic. The letter reads: Dear Friends, Your health and well-being are on our minds as we all deal with a national and glob
- Trump Touts Drug That FDA Says Isn’t Yet Approved for Virushttps://modernod.com/news/trump-touts-drug-that-fda-says-isnt-yet-approved-for-virus/2477422/The Food and Drug Administration has been told by President Donald Trump to see if it can expand the use of a decades-old malaria drug as an experimental treatment for coronavirus patients, as
- Johnson & Johnson Vision Calls on Individuals Worldwide to Prioritize Your Eyes in 2020https://modernod.com/news/johnson-johnson-vision-calls-on-individuals-worldwide-to-prioritize-your-eyes-in-2020/2477309/Johnson & Johnson Vision announced the launch of “Prioritize Your Eyes,” a worldwide effort to raise awareness about the connection of eye health to overall health. Prioritize Your Eyes encourages everyone to take the single most important step to protect their eyes—getting an eye
- Schwind Hosts 18th International User Meeting in Hamburghttps://modernod.com/news/schwind-hosts-18th-international-user-meeting-in-hamburg/2477306/A new attendance record was set at the 18th International Schwind User Meeting. Schwind reported that about 260 attendees from more than 50 countries met in Hamburg, Germany, January 23-25, 2020. The Schwind user fami
- IrisVision and Samsung Announce Partnership to Bring Clinically Validated Vision Technologies to Over 200 Million Low Vision Patients Globallyhttps://modernod.com/news/irisvision-and-samsung-announce-partnership-to-bring-clinically-validated-vision-technologies-to-over-200-million-low-vision-patients-globally/2477207/Samsung Electronics and IrisVision announced a strategic partnership to roll out IrisVision’s technology worldwide. IrisVision’s vision correction software platform uses the power of Samsung’s Galaxy smartphones, XR devices, and mobile AI platform to enable people
- Positive Phase 3 Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in NEJMhttps://modernod.com/news/positive-phase-3-results-for-genentechs-satralizumab-in-neuromyelitis-optica-spectrum-disorder-published-in-nejm/2477130/Genentech announced that data from SAkuraSky, a pivotal phase 3 study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the November 27, 2019 online issue of the New England Journal of Medicine (NEJM).
- Allergan Issues Recall for Certain Lots of Xen 45https://modernod.com/news/allergan-issues-recall-for-certain-lots-of-xen-45/2477061/Allergan has initiated a voluntary recall of its XEN 45 glaucoma drainage device after a small number of units in an unreleased lot were observed to have trace amounts of polishing compounds that are used in the needle sleeve manufacturing process, according to a joint news release with ASCRS.
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random
- Sight Sciences: International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI Surgical System Predicate Device (VISCO360)https://modernod.com/news/sight-sciences-international-migs-study-confirms-long-term-safety-and-efficacy-of-the-omni-surgical-system-predicate-device-visco360/2477032/Sight Sciences announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI